Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
718 patients across a multi-institutional cohort, all of whom underwent magnetic resonance imaging (MRI)-targeted biopsy.
I · Intervention 중재 / 시술
magnetic resonance imaging (MRI)-targeted biopsy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Treatment with 5-ARIs is associated with decreased detection of csPCa on MRI-targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false-positive mpMRI findings in patients receiving 5-ARIs.
[OBJECTIVES] To assess the impact of 5α-reductase inhibitors (5-ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging-Reporting and Data System (PI-RADS) lesions and
- p-value P = 0.04
- p-value P = 0.027
- 95% CI 0.05-0.68
APA
Das A, Bigarella M, et al. (2026). Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.. BJU international, 137(2), 332-338. https://doi.org/10.1111/bju.70067
MLA
Das A, et al.. "Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.." BJU international, vol. 137, no. 2, 2026, pp. 332-338.
PMID
41190378
Abstract
[OBJECTIVES] To assess the impact of 5α-reductase inhibitors (5-ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging-Reporting and Data System (PI-RADS) lesions and their influence on the detection of clinically significant prostate cancer (csPCa), with a focus on differences between prostate zones.
[PATIENTS AND METHODS] We retrospectively reviewed data from 1108 PI-RADS version 2 score 3-5 lesions in 718 patients across a multi-institutional cohort, all of whom underwent magnetic resonance imaging (MRI)-targeted biopsy. A subset of 66 lesions from patients receiving 5-ARI therapy was matched to lesions from untreated patients and independently reviewed by an experienced radiologist in a blinded fashion. Apparent diffusion coefficient (ADC) values were quantified for each lesion and for peripheral and transition zones.
[RESULTS] Among the 1108 lesions, 90 (8%) were in patients on 5-ARI therapy for ≥3 months prior to mpMRI. Multivariable analysis demonstrated that 5-ARI use was associated with significantly reduced odds of detecting csPCa on targeted biopsy (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.18-0.57). Stratified analysis revealed a pronounced reduction in csPCa detection in peripheral zone lesions (OR 0.20, 95% CI 0.05-0.68), but not in transition zone lesions (OR 0.38, 95% CI 0.11-1.18). Blinded radiological review showed higher mean ADC values in peripheral zone lesions among 5-ARI users (869 vs 765 mm/s; P = 0.04) and lower lesion conspicuity (P = 0.027). There were no significant imaging differences in the transition zone.
[CONCLUSIONS] Treatment with 5-ARIs is associated with decreased detection of csPCa on MRI-targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false-positive mpMRI findings in patients receiving 5-ARIs.
[PATIENTS AND METHODS] We retrospectively reviewed data from 1108 PI-RADS version 2 score 3-5 lesions in 718 patients across a multi-institutional cohort, all of whom underwent magnetic resonance imaging (MRI)-targeted biopsy. A subset of 66 lesions from patients receiving 5-ARI therapy was matched to lesions from untreated patients and independently reviewed by an experienced radiologist in a blinded fashion. Apparent diffusion coefficient (ADC) values were quantified for each lesion and for peripheral and transition zones.
[RESULTS] Among the 1108 lesions, 90 (8%) were in patients on 5-ARI therapy for ≥3 months prior to mpMRI. Multivariable analysis demonstrated that 5-ARI use was associated with significantly reduced odds of detecting csPCa on targeted biopsy (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.18-0.57). Stratified analysis revealed a pronounced reduction in csPCa detection in peripheral zone lesions (OR 0.20, 95% CI 0.05-0.68), but not in transition zone lesions (OR 0.38, 95% CI 0.11-1.18). Blinded radiological review showed higher mean ADC values in peripheral zone lesions among 5-ARI users (869 vs 765 mm/s; P = 0.04) and lower lesion conspicuity (P = 0.027). There were no significant imaging differences in the transition zone.
[CONCLUSIONS] Treatment with 5-ARIs is associated with decreased detection of csPCa on MRI-targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false-positive mpMRI findings in patients receiving 5-ARIs.
MeSH Terms
Humans; Male; Prostatic Neoplasms; 5-alpha Reductase Inhibitors; Retrospective Studies; Multiparametric Magnetic Resonance Imaging; Aged; Middle Aged; Prostate; Image-Guided Biopsy
같은 제1저자의 인용 많은 논문 (5)
- From STORM to steadier ground: refining radiotherapy for nodal oligorecurrent prostate cancer.
- Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress.
- Peptide receptor radionuclide therapy: a new era of radiation nephropathy.
- A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.
- Molecular Advances in Gastrointestinal Pathology.